DJIA 15,973.84 313.66 2.00%
NASDAQ 4,337.51 70.68 1.66%
S&P 500 1,864.78 35.70 1.95%
market minute promo

0.22 0.01 (4.06%)

Quote as of


company name or ticker

Recent Quotes

IMUC $0.22 4.06%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.21
Previous Close $0.21
Daily Range $0.21 - $0.23
52-Week Range $0.20 - $0.65
Market Cap $20.1M
P/E Ratio -1.65
Dividend (Yield) $0.00 (0.0%)
Volume 70,770
Average Daily Volume 331,511
Current FY EPS -$0.13

Sector

Healthcare

Industry

Healthcare IT

ImmunoCellular Therapeutics, Ltd. (IMUC) Description

ImmunoCellular Therapeutics, Ltd. Website: http://www.imuc.com/

News & Commentary

3 Possible Catalysts for Inovio Pharmaceuticals in 2014

Inovio Pharmaceuticals could be a stock to watch in 2014 for these three reasons.

With Approval Likely, Celldex Needs To Expand Commercial Capabilities

Caladrius Bio From Pawnshop To Boutique

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at th

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015

ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2015 Results - Earnings Call Transcript

ImmunoCellular Announces Update on ICT-107

ImmunoCellular Therapeutics Letter to Shareholders Highlights Progress on Advancing ICT-107 to Phase

ImmunoCellular Therapeutics Letter to Shareholders Highlights Progress on Advancing ICT-107 to Phase 3 Registrational Trial

Health Care Sector Update for 08/13/2015: OCUL, IMUC

ImmunoCellular's (IMUC) CEO Andrew Gengos on Q1 2015 Results - Earnings Call Transcript

Next Week In Biotech: Salix/Valeant PDUFA, ASCO, Brain Tumor Summit

ImmunoCellular's (IMUC) CEO Andrew Gengos on Q1 2015 Results - Earnings Call Transcript

See More IMUC News...

IMUC's Top Competitors

IMUC $0.22 (4.06%)
Current stock: IMUC
JNJ $101.82 (0.12%)
Current stock: JNJ
NVS $72.70 (0.69%)
Current stock: NVS
RHHBY $31.27 (0.42%)
Current stock: RHHBY